NCT06899061 2026-03-03
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
AstraZeneca
Phase 1 Active not recruiting
Clinical Trials
27 trialsNCT06760481 2026-02-24
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07368478 2026-01-26
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
Biocity Biopharmaceutics Co., Ltd.
Phase 1 Recruiting
NCT06388902 2025-11-21
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT06028074 2025-07-11
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Georgiamune Inc
Phase 1/2 Recruiting
NCT04521413 2025-05-21
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Treadwell Therapeutics, Inc
Phase 1/2 Active not recruiting
NCT02398747 2024-12-17
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT05469919 2024-08-02
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02347228 2024-01-26
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
Oneness Biotech Co., Ltd.
Phase 1 Unknown
NCT04353102 2022-07-22
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT04136834 2021-08-17
PT01
Athenex, Inc.
Phase 1 Unknown
NCT00669097 2020-12-21
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
Novartis
Phase 1 Completed
NCT03980821 2020-12-08
A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT01058707 2020-04-01
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT03736473 2019-07-08
A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients
AstraZeneca
Phase 1 Completed
NCT03394144 2019-06-24
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02350868 2019-04-11
Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment
Taipei Medical University
Phase 1 Completed
NCT01103791 2017-05-05
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
Samyang Biopharmaceuticals Corporation
Phase 1 Completed
NCT00871559 2014-03-26
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT01455584 2013-05-23
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT00986843 2013-04-05
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT00979563 2011-12-07
Oratecan-101
Hanmi Pharmaceutical Company Limited
Phase 1 Completed
NCT00981721 2011-06-20
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT00997945 2011-05-19
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT00295243 2011-01-13
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
Mayo Clinic
Phase 1 Completed
NCT01024283 2009-12-02
Analysis of Pharmacodynamic Changes With AUY922A, an HSP90 Inhibitor
Royal Marsden NHS Foundation Trust
Unknown
NCT00351325 2009-09-04
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated